Nippon Shinyaku gains Japanese rights to Labopharm's once-daily tramadol
This article was originally published in Scrip
The mid-sized Japanese company Nippon Shinyaku has acquired exclusive development and commercial rights in its home market to Labopharm's once-daily oral formulation of the analgesic tramadol.
You may also be interested in...ï»¿
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.